Actelion outlines new strategic plans for growth

Actelion has outlined three key strategic objectives that are essential to its future plans for growth during an investor event in London.

The pharmaceutical company will be pursuing these goals with the aim of producing stable core earnings in 2013, followed by a return to growth in 2014 before ultimately securing double-digit improvements the year after.

To accomplish this, the company will aim to expand its pulmonary arterial hypertension market, leveraging the potential offered by developmental compounds such as selexipag and macitentan.

Last month, the firm published positive phase III clinical trial data on macitentan that will hopefully support regulatory submissions to health authorities planned for the fourth quarter of 2012.

Meanwhile, research and development activities will be refocused towards specialty markets, while further efforts will be dedicated towards cost-saving programmes.

Jean-Paul Clozel, managing director and chief executive officer of Actelion, said: "The strength of our pipeline and our renewed efforts to optimise profitability will produce a bright future for Actelion."